<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">russjcardiol</journal-id><journal-title-group><journal-title xml:lang="ru">Российский кардиологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Journal of Cardiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-4071</issn><issn pub-type="epub">2618-7620</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1560-4071-2021-4158</article-id><article-id custom-type="elpub" pub-id-type="custom">russjcardiol-4158</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИКА И ФАРМАКОТЕРАПИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CLINIC AND PHARMACOTHERAPY</subject></subj-group></article-categories><title-group><article-title>Влияние комбинированной гипотензивной терапии, включающей блокаторы ренин-ангиотензинальдостероновой системы, на показатели оксидативного стресса и ремоделирования артериальной стенки у больных с сердечной недостаточностью с сохраненной фракцией выброса на фоне артериальной гипертонии</article-title><trans-title-group xml:lang="en"><trans-title>Effect of combination antihypertensive therapy, including renin-angiotensin-aldosterone system inhibitors, on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3187-5737</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ахильгова</surname><given-names>З. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Akhilgova</surname><given-names>Z. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ахильгова Зарина Макшариповна — аспирант кафедры терапии и подростковой медицины</p><p>Москва</p></bio><bio xml:lang="en"><p>Akhilgova  Zarina M. - Post-Graduated Student, Chair of Therapy and Teenage Medicin</p><p>Moscow</p></bio><email xlink:type="simple">zarina.akhilgova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2592-6857</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ройтман</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Roitman</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ройтман Александр Польевич — доктор медицинских наук, профессор кафедры клинической лабораторной диагностики</p><p>Москва</p></bio><bio xml:lang="en"><p>Roitman  Alexandr P. - MD, PhD, Professor, Chair of Clinical Laboratory Diagnostics</p><p>Moscow</p></bio><email xlink:type="simple">a-roitman@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1168-6795</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ракова</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Rakova</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ракова Наталия Геннадьевна — кандидат медицинских наук, доцент кафедры клинической лабораторной диагностики</p><p>Москва</p></bio><bio xml:lang="en"><p>Rakova  Nataliya G. - MD, PhD, Chair of Clinical Laboratory Diagnostics</p><p>Moscow</p></bio><email xlink:type="simple">n_rakova@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1404-4699</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бугров</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Bugrov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Бугров Алексей Викторович — кандидат медицинских наук, доцент кафедры клинической лабораторной диагностики</p><p>Москва</p></bio><bio xml:lang="en"><p>Bugrov  Alexey V. - MD, PhD, Chair of Clinical Laboratory Diagnostics</p><p>Moscow</p></bio><email xlink:type="simple">avb81@bk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5652-1580</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павловская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlovskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павловская Евгения Анатольевна — кандидат медицинских наук, заведующий 11 кардиологического отделения, ассистент кафедры терапии и подростковой медицины</p><p>Москва</p></bio><bio xml:lang="en"><p>Pavlovskaya  Evgeniya A. - MD, PhD, Head of Cardiology Department №11, V.V. Veresaev City Clinical Hospital. Assistant, Chair of Therapy and Teenage Medicine, Russian Medical Academy of Continuous Professional Education</p><p>Moscow</p><p> </p></bio><email xlink:type="simple">zhenyaermakova@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0607-4812</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Застрожин</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Zastrozhin</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Застрожин Михаил Сергеевич — кандидат медицинских наук, доцент кафедры наркологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">mszastrozhin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8967-0902</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Автандилов</surname><given-names>А. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Avtandilov</surname><given-names>A. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Автандилов Александр Георгиевич — доктор медицинских наук, профессор, заведующий кафедры терапии и подростковой медицины</p><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><email xlink:type="simple">algav@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздрава России;&#13;
Городская клиническая больница им. В.В. Вересаева</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Russian Medical Academy of Continuous Professional Education;&#13;
V.V. Veresaev City Clinical Hospital</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>30</day><month>04</month><year>2021</year></pub-date><volume>26</volume><issue>5</issue><fpage>4158</fpage><lpage>4158</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ахильгова З.М., Ройтман А.П., Ракова Н.Г., Бугров А.В., Павловская Е.А., Застрожин М.С., Автандилов А.Г., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Ахильгова З.М., Ройтман А.П., Ракова Н.Г., Бугров А.В., Павловская Е.А., Застрожин М.С., Автандилов А.Г.</copyright-holder><copyright-holder xml:lang="en">Akhilgova Z.M., Roitman A.P., Rakova N.G., Bugrov A.V., Pavlovskaya E.A., Zastrozhin M.S., Avtandilov A.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://russjcardiol.elpub.ru/jour/article/view/4158">https://russjcardiol.elpub.ru/jour/article/view/4158</self-uri><abstract><sec><title>Цель</title><p>Цель. Изучить влияние тройной комбинированной терапии на показатели оксидативного стресса и ремоделирования артериальной стенки у больных с сердечной недостаточностью с сохраненной фракцией выброса (СНсФВ) на фоне артериальной гипертонии.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследовании участвовали 76 человек с диагностированной СНсФВ. После комплексного обследования проводилась рандомизация больных на две равные группы с назначением терапии: в первой группе — периндоприл 10 мг, индапамид 2,5 мг и амлодипин 5 мг; во второй — лозартан 100 мг, индапамид 2,5 мг, амлодипин 5 мг. До и через 16 нед. после начала терапии проводилось ультразвуковое исследование сердца с определением параметров диагностики СНсФВ, оценка функции эндотелия с расчетом эндотелийзависимой вазодилатации, оценка ригидности стенки сосудов методами фотоплетизмографии и объемной компрессионной осциллометрии, а также маркера оксидативного стресса — концентрации 8-изопростана в плазме крови.</p></sec><sec><title>Результаты</title><p>Результаты. За время наблюдения отмечено значимое улучшение эндотелиальной функции: в первой группе больных — с 8,1% до 11,4% (р=0,001), во второй — с 5,8% до 8,3% (р=0,0007). В обеих группах отмечалось улучшение эластических свойств микроциркуляторного русла: достоверное снижение удельного периферического сопротивления, а также статистически значимое снижение общего периферического сопротивления в первой группе (р&lt;0,002) и тенденцию к его снижению во второй (р&gt;0,05). При оценке жесткости сосудистой стенки отмечалось достоверное повышение ригидности аорты и артерий мышечного типа в обеих группах: снижение индекса жесткости в первой группе с 10,38 м/с до 8,33 м/с (р&lt;0,0001), во второй — с 10,6 м/с до 9,3 м/с (р&lt;0,01), и индекса резистивности: в первой группе — с 71,5% до 60,4% (р&lt;0,0001), во второй — с 68% до 60% (р=0,006). Также в обеих группах выявлено достоверное уменьшение размера левого предсердия в фазу диастолы и снижение индекса объема левого предсердия. Отмечено снижение концентрации 8-изопростана в плазме крови, что свидетельствует об уменьшении оксидативного стресса.</p></sec><sec><title>Заключение</title><p>Заключение. Оксидативный стресс, развивающийся на фоне хронического системного воспаления, играет ключевую роль в патогенезе развития СНсФВ. Полученные результаты показывают улучшение эндотелиальной функции на фоне снижения оксидативного стресса, что сопровождается улучшением эластических свойств сосудистой стенки, тем самым замедляя прогрессирование данного синдрома.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Aim</title><p>Aim. To study the effect of triple combination therapy on oxidative stress and arterial remodeling in hypertensive patients with heart failure with preserved ejection fraction (HFpEF).</p></sec><sec><title>Material and methods</title><p>Material and methods. The study involved 76 people with diagnosed HFpEF. After a comprehensive examination, patients were randomized into two equal groups: first group — patients who received perindopril 10 mg, indapamide 2,5mg and amlodipine 5 mg; second — patients who received losartan 100 mg, indapamide 2,5 mg, amlodipine 5 mg. Before and 16 weeks after the therapy initiation, cardiac ultrasound, assessment of endothelial function with estimating endothelium-dependent vasodilation, assessment of vascular stiffness by photoplethysmography and compression oscillometry were carried out. The plasma concentration of oxidative stress marker 8-isoprostane was studied.</p></sec><sec><title>Results</title><p>Results. During the follow-up period, a significant improvement in endothelial function was noted: in the first group — from 8,1% to 11,4% (p=0,001), in the second — from 5,8% to 8,3% (p=0,0007). In both groups, there was an improvement in microvessel elasticity: a significant decrease in specific peripheral vascular resistance, as well as a significant decrease in total peripheral resistance in the first group (p&lt;0,002) and a tendency to decrease in the second one (p&gt;0,05). There was a significant increase in the stiffness of the aorta and muscular arteries in both groupsю In the first group, a stiffness index decreased from 10,38 m/s to 8,33 m/s (p&lt;0,0001), in the second — from 10,6 m/s to 9,3 m/s (p&lt;0,01). In addition, resistance index in the first group decreased from 71,5% to 60% (p&lt;0,0001), while in the second — from 68% to 60% (p=0,006). Also, both groups showed a significant decrease in the left atrial diastolic dimension and the left atrial volume index. A decrease in the 8-isoprostane plasma levels was noted, which indicates a decrease in oxidative stress.</p></sec><sec><title>Conclusion</title><p>Conclusion. Oxidative stress, which develops due to chronic systemic inflammation, plays a key role in the pathogenesis of HFpEF. The results obtained show an improved endothelial function as a result of decrease in oxidative stress, which is accompanied by an improvement in vessel wall elasticity, thereby slowing down the heart failure progression.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>эндотелиальная дисфункция</kwd><kwd>оксидативный стресс</kwd><kwd>сердечная недостаточность с сохраненной фракцией выброса</kwd></kwd-group><kwd-group xml:lang="en"><kwd>endothelial dysfunction</kwd><kwd>oxidative stress</kwd><kwd>heart failure with preserved ejection fraction</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016;375(19):1868-77. doi:10.1056/NEJMcp1511175.</mixed-citation><mixed-citation xml:lang="en">Redfield MM. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2016;375(19):1868-77. doi:10.1056/NEJMcp1511175.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. doi:10.1016/j.jacc.2013.02.092.</mixed-citation><mixed-citation xml:lang="en">Paulus WJ, Tschöpe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263-71. doi:10.1016/j.jacc.2013.02.092.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Premer C, Kanelidis AJ, Hare JM, et al. Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. Mayo Clin Proc Inn Qual Out. 2019;3(1):1-13. doi:10.1016/j.mayocpiqo.2018.12.006.</mixed-citation><mixed-citation xml:lang="en">Premer C, Kanelidis AJ, Hare JM, et al. Rethinking Endothelial Dysfunction as a Crucial Target in Fighting Heart Failure. Mayo Clin Proc Inn Qual Out. 2019;3(1):1-13. doi:10.1016/j.mayocpiqo.2018.12.006.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Pol A, Gilst WH, Voors AA, et al. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019;21(4):425-35. doi:10.1002/ejhf.1320.</mixed-citation><mixed-citation xml:lang="en">Pol A, Gilst WH, Voors AA, et al. Treating oxidative stress in heart failure: past, present and future. Eur J Heart Fail. 2019;21(4):425-35. doi:10.1002/ejhf.1320.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Libby P. Once more unto the breach: endothelial permeability and atherogenesis. Eur Heart J. 2019;40(11):938-40. doi:10.1093/eurheartj/ehz081.</mixed-citation><mixed-citation xml:lang="en">Libby P. Once more unto the breach: endothelial permeability and atherogenesis. Eur Heart J. 2019;40(11):938-40. doi:10.1093/eurheartj/ehz081.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Vimercati C, Qanud K, Mitacchione G, et al. Beneficial effects of acute inhibition of the oxidative pentose phosphate pathway in the failing heart. Am J Physiol Heart Circ Physiol. 2014;306(5):H709-17. doi:10.1152/ajpheart.00783.2013.</mixed-citation><mixed-citation xml:lang="en">Vimercati C, Qanud K, Mitacchione G, et al. Beneficial effects of acute inhibition of the oxidative pentose phosphate pathway in the failing heart. Am J Physiol Heart Circ Physiol. 2014;306(5):H709-17. doi:10.1152/ajpheart.00783.2013.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.</mixed-citation><mixed-citation xml:lang="en">Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37(27):2129-200. doi:10.1093/eurheartj/ehw128.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Мареев В.Ю., Фомин И.В., Агеев Ф.Т. и др. Клинические рекомендации ОССН РКО РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-158. doi:10.1007/s00059-013-3986-9.</mixed-citation><mixed-citation xml:lang="en">Mareev VY, Fomin IV, Ageev FT, et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8-158. (In Russ.) doi:10.1007/s00059-013-3986-9.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Massie BM, Carson PE, McMurray JJ. I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. doi:10.1056/NEJMoa0805450.</mixed-citation><mixed-citation xml:lang="en">Massie BM, Carson PE, McMurray JJ. I-PRESERVE Investigators Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359(23):2456-67. doi:10.1056/NEJMoa0805450.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ахильгова З.М., Куркина М.В., Джиоева З.Р. и др. Диагностика и спорные вопросы лечения сердечной недостаточности с сохраненной фракцией выброса. Кардиосоматика. 2018;(4):32-7. doi:10.26442/22217185.2018.4.000013.</mixed-citation><mixed-citation xml:lang="en">Akhilgova ZM, Kurkina MV, Dzhioeva ZR, et al. Diagnosis and the debatable issues of the treatment of heart failure with preserved ejection fraction. Cardiosomatics. 2018;(4):32-7. (In Russ.) doi:10.26442/22217185.2018.4.000013.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Silva IVG, de Figueiredo RC, Rios DRA. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation. Int J Mol Sci. 2019;20(14):3458. doi:10.3390/ijms20143458.</mixed-citation><mixed-citation xml:lang="en">Silva IVG, de Figueiredo RC, Rios DRA. Effect of Different Classes of Antihypertensive Drugs on Endothelial Function and Inflammation. Int J Mol Sci. 2019;20(14):3458. doi:10.3390/ijms20143458.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351-6. doi:10.2337/dc06-1551.</mixed-citation><mixed-citation xml:lang="en">Schmieder RE, Delles C, Mimran A, et al. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. Diabetes Care. 2007;30:1351-6. doi:10.2337/dc06-1551.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221(1):18-33. doi:10.1016/j.atherosclerosis.2011.12.005.</mixed-citation><mixed-citation xml:lang="en">Shahin Y, Khan JA, Chetter I. Angiotensin converting enzyme inhibitors effect on arterial stiffness and wave reflections: a meta-analysis and meta-regression of randomised controlled trials. Atherosclerosis. 2012;221(1):18-33. doi:10.1016/j.atherosclerosis.2011.12.005.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yen CH, Lai YH, Hung CL, et al. Angiotensin Receptor Blockades Effect on Peripheral Muscular and Central Aortic Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials and Systematic Review. Acta Cardiol Sin. 2014;30(2):98-107.</mixed-citation><mixed-citation xml:lang="en">Yen CH, Lai YH, Hung CL, et al. Angiotensin Receptor Blockades Effect on Peripheral Muscular and Central Aortic Arterial Stiffness: A Meta-Analysis of Randomized Controlled Trials and Systematic Review. Acta Cardiol Sin. 2014;30(2):98-107.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Khan MS, Fonarow GC, Khan H, et al. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2017;4(4):402-8. doi:10.1002/ehf2.12204.</mixed-citation><mixed-citation xml:lang="en">Khan MS, Fonarow GC, Khan H, et al. Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Fail. 2017;4(4):402-8. doi:10.1002/ehf2.12204.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Yip G, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573-80. doi:10.1136/hrt.2007.117978.</mixed-citation><mixed-citation xml:lang="en">Yip G, Wang M, Wang T, et al. The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction. Heart. 2008;94(5):573-80. doi:10.1136/hrt.2007.117978.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013;125(4):154-68. doi:10.3810/pgm.2013.07.2687.</mixed-citation><mixed-citation xml:lang="en">Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril. Postgrad Med. 2013;125(4):154-68. doi:10.3810/pgm.2013.07.2687.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">de Faria AP, Fontana V, Modolo R, et al. Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension. Clin Chim Acta. 2014;433:179-83. doi:10.1016/j.cca.2014.03.009.</mixed-citation><mixed-citation xml:lang="en">de Faria AP, Fontana V, Modolo R, et al. Plasma 8-isoprostane levels are associated with endothelial dysfunction in resistant hypertension. Clin Chim Acta. 2014;433:179-83. doi:10.1016/j.cca.2014.03.009.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
